Plaintiffs allege that the drug, prescribed for type 2 diabetes and weight loss, caused serious gastrointestinal complications, including gastroparesis
Interestingly, NRF2 is able to inhibit the activation of inflammatory genes without binding to the ARE sequence
In the previous discussion on advancements in needleless injections, we hinted at their transformative power
At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial
Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx